PMID- 27416087
OWN - NLM
STAT- MEDLINE
DCOM- 20170418
LR  - 20181202
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 97
IP  - 6
DP  - 2016 Jun
TI  - Novel melanoma therapies and their side effects.
PG  - 426-8
AB  - In the last few years, melanoma treatment has been revolutionized by the 
      development of immune checkpoint-blocking antibodies or immune checkpoint 
      inhibitors including ipilimumab, vemurafenib, dabrafenib, trametinib, nivolumab, 
      and pembrolizumab. Although they have shown promising results, they also have 
      caused multiple adverse events (AEs), particularly immune-related AEs (irAEs). 
      Specialists should be familiar with these AEs.
FAU - Gonzalez, Noelani
AU  - Gonzalez N
AD  - Icahn School of Medicine at Mount Sinai, New York, New York, USA.
FAU - Ratner, Desiree
AU  - Ratner D
AD  - Icahn School of Medicine at Mount Sinai and Mount Sinai Beth Israel, New York, 
      New York, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Imidazoles)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Indoles)
RN  - 0 (Ipilimumab)
RN  - 0 (Oximes)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207SMY3FQT (Vemurafenib)
RN  - 31YO63LBSN (Nivolumab)
RN  - 33E86K87QN (trametinib)
RN  - DPT0O3T46P (pembrolizumab)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Chemical and Drug Induced Liver Injury/drug therapy/etiology
MH  - Drug Eruptions/etiology
MH  - Gastrointestinal Diseases/chemically induced/drug therapy
MH  - Humans
MH  - Hypophysitis/chemically induced/drug therapy
MH  - Hypothyroidism/chemically induced/drug therapy
MH  - Imidazoles/adverse effects
MH  - Immunosuppressive Agents/therapeutic use
MH  - Indoles/adverse effects
MH  - Ipilimumab
MH  - Melanoma/*drug therapy
MH  - Mycophenolic Acid/therapeutic use
MH  - Nivolumab
MH  - Oximes/adverse effects
MH  - Pyridones/adverse effects
MH  - Pyrimidinones/adverse effects
MH  - Skin Neoplasms/*drug therapy
MH  - Sulfonamides/adverse effects
MH  - Sweet Syndrome/chemically induced
MH  - Thyrotoxicosis/chemically induced/drug therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - Vemurafenib
MH  - Vitiligo/chemically induced
EDAT- 2016/07/16 06:00
MHDA- 2017/04/19 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/16 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PST - ppublish
SO  - Cutis. 2016 Jun;97(6):426-8.